SLNO Soleno Therapeutics Corp: Rasio rega marang prakiraan pendapatan

Soleno Therapeutics - logo grafis emiten SLNO

Soleno Therapeutics (SLNO) is developing DCCR, a unique drug for the treatment of Prader-Willi syndrome, holding exclusive orphan drug status. A team of elite endocrinologists is driving innovation supported by robust laboratory funding. The humanitarian nature of these projects minimizes geopolitical risks and sanctions. The future P/S multiple reflects the business valuation dynamics, where the value 2.40 serves as the baseline indicator of current market value.

Soleno Therapeutics, Inc. - Rasio kapitalisasi marang dodolan sing dikarepake SLNO (periode 08.08.2025 - 30.05.2026)

Ringkesan rincian data analitis soleno.life (SLNO)

- rega pasar lan target rega analis:
Analisis komprehensif perusahaan:SLNO (soleno.life)
Produk asli Soleno Therapeutics

The forward P/S ratio relates the current market value of the business to expected sales volume, allowing investors to assess the premium paid for future growth without the delays associated with quarterly reports. By analyzing the projected price-to-sales valuation, one can filter out speculative noise, which is critical for Soleno Therapeutics (SLNO), where the automation of drug synthesis accelerates development, yet final capitalization depends on lengthy clinical trials.

Analisis pesaing

Rasio rega marang prakiraan pendapatan ascendispharma.com ASND|Madrigal Corp (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake Corp|Crinetics Corp (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan newamsterdampharma.com (NAMS)|Multiplikator forward rega marang pendapatan Amicus Therapeutics FOLD|Rega forward marang dodolan 89bio Inc|Multiplikator Forward P/S Agios Pharmaceuticals, Inc. AGIO|GPCR: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake MiMedx Corp MDXG|RZLT (Rezolute Corp) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan LXRX|MBX (MBX Biosciences) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Altimmune Inc (ALT)|Multiplikator forward rega marang pendapatan AARD (Aardvark Therapeutics Corp)|Multiplikator forward rega marang pendapatan Sagimet SGMT|Multiplikator Forward P/S BIOA (BioAge Labs)|Multiplikator Forward P/S Biomea Fusion BMEA|QNCX: Multiplikator forward rega marang pendapatan|GUTS: Rasio rega marang prakiraan pendapatan|vTv Therapeutics Inc (VTVT) - Rasio rega marang prakiraan pendapatan|ATPC: Rasio rega marang pendapatan sing dikarepake|PLUR (pluri-biotech.com) - Multiplikator Forward P/S|SYBX: Rega forward marang dodolan|Multiplikator Forward P/S LPCN|Rasio kapitalisasi marang dodolan sing dikarepake Matinas BioPharma Holdings, Inc.|Rasio rega marang prakiraan pendapatan Spruce Biosciences Inc. SPRB|GLTO - Multiplikator forward rega marang pendapatan|CTCX - Rasio rega marang prakiraan pendapatan|LUMO - Multiplikator Forward P/S|ONVO: Multiplikator Forward P/S|RDUS (Radius Recycling) - Rasio rega marang prakiraan pendapatan